The short version
Only one company currently supplies this market — there is no backup if it stumbles.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Kanka Triple Action
BENZOCAINE and MENTHOL, UNSPECIFIED FORM · BENZOCAINE 20 g/100g; MENTHOL, UNSPECIFIED FORM 2 g/100g · Gel · Oral · Blistex Inc.
NDC 10157-2127-01 · 1 TUBE in 1 CARTON / 11.9 g in 1 TUBE · OTC MONOGRAPH DRUG · View full market →
Medicare Part D
Medicare Part D does not cover over-the-counter drugs — by law it pays only for products requiring a prescription.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Regulatory
- Application
- M022
- TE code
- —
- Approval date
- —
- Patents / exclusivity
- None on file
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of BENZOCAINE and MENTHOL, UNSPECIFIED FORM (Gel)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Blistex Inc. | BENZOCAINE 20 g/100g; MENTHOL, UNSPECIFIED FORM 2 g/100g | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Kanka Triple Action — NDC 10157-2127-01," retrieved September 3, 2026, https://drugdashboards.com/drug/10157212701.
Free to cite with attribution — see how the data is put together.